Pancreatic Cancer Research

ResearcherSecond Military Medical UniversityActive in the last 2 years

Jianping Lu

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-0380-7470; OpenAlex author ID A5047591121. Sources: OpenAlex.

Their work

Papers
22 (first author 0, last author 12)
Trials
0
Grants
0
Labs led
1
Collaborators
43
Papers, trials and grants by year

2015: 1 paper · 2016: none · 2017: 2 papers · 2018: 2 papers · 2019: none · 2020: 1 paper · 2021: 6 papers · 2022: 7 papers · 2023: 2 papers · 2024: 1 paper

Papers 22

  1. Values of apparent diffusion coefficient in pancreatic cancer patients receiving neoadjuvant therapy. Last author DOI 10.1186/s12885-024-12934-y↗
  2. Large-scale pancreatic cancer detection via non-contrast CT and deep learning. Last author DOI 10.1038/s41591-023-02640-w↗
  3. Tumor size measurements of pancreatic cancer with neoadjuvant therapy based on RECIST guidelines: is MRI as effective as CT? Last author DOI 10.1186/s40644-023-00528-z↗
  4. Preoperative Radiomics Approach to Evaluating Tumor-Infiltrating CD8+ T Cells in Patients With Pancreatic Ductal Adenocarcinoma Using Noncontrast Magnetic Reso… Last author DOI 10.1002/jmri.27871↗
  5. Contrast-enhanced computed tomography radiomics and multilayer perceptron network classifier: an approach for predicting CD20+ B cells in patients with pancrea… Last author DOI 10.1007/s00261-021-03285-4↗
  6. CT Radiomics Features in Differentiation of Focal-Type Autoimmune Pancreatitis from Pancreatic Ductal Adenocarcinoma: A Propensity Score Analysis. Co-author DOI 10.1016/j.acra.2021.04.014↗
  7. Magnetic Resonance Radiomics and Machine-learning Models: An Approach for Evaluating Tumor-stroma Ratio in Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1016/j.acra.2021.08.013↗
  8. Prediction of Tumor-Infiltrating CD20+ B-Cells in Patients with Pancreatic Ductal Adenocarcinoma Using a Multilayer Perceptron Network Classifier Based on Non-… Co-author DOI 10.1016/j.acra.2021.11.013↗
  9. Machine Learning for Computed Tomography Radiomics: Prediction of Tumor-Infiltrating Lymphocytes in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/mpa.0000000000002069↗
  10. Radiomics nomogram for the preoperative prediction of lymph node metastasis in pancreatic ductal adenocarcinoma. Last author DOI 10.1186/s40644-021-00443-1↗
  11. Noncontrast Magnetic Resonance Radiomics and Multilayer Perceptron Network Classifier: An approach for Predicting Fibroblast Activation Protein Expression in P… Co-author DOI 10.1002/jmri.27648↗
  12. Machine learning for MRI radiomics: a study predicting tumor-infiltrating lymphocytes in patients with pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00261-021-03159-9↗
  13. The relationship between microscopic tumor size and CT tumor size in pancreatic ductal adenocarcinoma. Last author DOI 10.1016/j.clinimag.2020.11.039↗
  14. DeepPrognosis: Preoperative prediction of pancreatic cancer survival and surgical margin via comprehensive understanding of dynamic contrast-enhanced CT imagin… Co-author DOI 10.1016/j.media.2021.102150↗
  15. XGBoost Classifier Based on Computed Tomography Radiomics for Prediction of Tumor-Infiltrating CD8+ T-Cells in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.671333↗
  16. CT Radiomics and Machine-Learning Models for Predicting Tumor-Stroma Ratio in Patients With Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.3389/fonc.2021.707288↗
  17. Pancreatic adenocarcinoma: variability in measurements of tumor size among computed tomography, magnetic resonance imaging, and pathologic specimens. Last author DOI 10.1007/s00261-019-02125-w↗
  18. Combination of Pre-Treatment DWI-Signal Intensity and S-1 Treatment: A Predictor of Survival in Patients with Locally Advanced Pancreatic Cancer Receiving Ster… Co-author DOI 10.1016/j.tranon.2018.01.012↗
  19. Pre-treatment DWI as a predictor of overall survival in locally advanced pancreatic cancer treated with Cyberknife radiotherapy and sequential S-1 therapy. Last author DOI 10.1186/s40644-018-0139-7↗
  20. Effect of region of interest size on ADC measurements in pancreatic adenocarcinoma. Last author DOI 10.1186/s40644-017-0116-6↗
  21. Aberrant expression of STYK1 and E-cadherin confer a poor prognosis for pancreatic cancer patients. Last author DOI 10.18632/oncotarget.22794↗
  22. Comparison of the Diagnostic Performances of Three Techniques of ROI Placement for ADC Measurements in Pancreatic Adenocarcinoma. Last author DOI 10.1016/j.acra.2015.06.017↗

Closest collaborators

The 25 strongest of 43 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Yun Bian · 16 shared papers, 2017–2024 · strength 2.14
  2. Chengwei Shao · 15 shared papers, 2017–2024 · strength 1.93
  3. Chao Ma · 12 shared papers, 2015–2024 · strength 1.46
  4. Hui Jiang · 9 shared papers, 2021–2023 · strength 1.11
  5. Yinghao Meng · 9 shared papers, 2021–2022 · strength 1.10
  6. Jieyu Yu · 9 shared papers, 2021–2022 · strength 1.10
  7. Li Wang · 10 shared papers, 2015–2022 · strength 1.08
  8. Kai Cao · 8 shared papers, 2021–2023 · strength 0.98
  9. Panpan Yang · 3 shared papers, 2020–2024 · strength 0.52
  10. Jing Li · 4 shared papers, 2021–2022 · strength 0.45
  11. Yufei Chen · 2 shared papers, 2023–2024 · strength 0.39
  12. Gang Jin · 3 shared papers, 2021–2023 · strength 0.38
  13. Luguang Chen · 2 shared papers, 2017–2024 · strength 0.28
  14. Qi Li · 2 shared papers, 2021–2022 · strength 0.25
  15. Jiawen Yao · 2 shared papers, 2021–2023 · strength 0.25
  16. Ling Zhang · 2 shared papers, 2021–2023 · strength 0.25
  17. Yu Shi · 2 shared papers, 2021–2023 · strength 0.25
  18. Qi Li · 2 shared papers, 2021–2022 · strength 0.24
  19. Hao Zhang · 2 shared papers, 2021 · strength 0.22
  20. Xiaofei Zhu · 2 shared papers, 2018 · strength 0.18
  21. Jun Wang · 1 shared paper, 2023 · strength 0.18
  22. Jianming Zheng · 1 shared paper, 2021 · strength 0.14
  23. Suizhi Gao · 1 shared paper, 2022 · strength 0.14
  24. Shiwei Guo · 1 shared paper, 2022 · strength 0.14
  25. Jianming Zheng · 1 shared paper, 2022 · strength 0.14

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.